US FDA’s 2022 Novel Agent Actions Suggest Acceleration In Use Of Complete Response Letters

 
• By Bridget Silverman

COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.

FDA Complete response stamp holder
US FDA has been using its "complete response" stamp more frequently. • Source: Nielsen Hobbs; the Pink Sheet | Alamy image

More from Complete Response Letters

More from Product Reviews